(Reuters) - The U.S. Federal Trade Commission said it has approved certain modifications to medical device company Boston Scientific (NYSE:BSX) Corp’s divestiture agreements.
"The FTC approved these agreements and incorporated them into its order as part of a consent agreement it required in 2019, when Boston Scientific acquired medical equipment and pharmaceutical supplier BTG plc," the FTC said in a statement https:// on Friday.
As a condition of Boston Scientific's acquisition of BTG, the FTC required it to divest to Varian Medical Systems (NYSE:VAR) its Drug Eluding Beads (DEBs) and bland beads business, the FTC said.